Irvine, CA, October 4, 2004 – Next Pharmaceuticals has completed a new double-blind placebo-controlled trial on the natural anti-inflammatory and painkilling effects of Nexrutine®. The study, conducted by Miami Research Associates, under the direction of Diane Krieger, MD, showed that Nexrutine® significantly improved quality of life issues. The post-treatment scores on the SF-36v2 Quality of Life instrument were improved significantly from the pre-treatment scores in the Nexrutine® group for Role Physical, Vitality, Mental Health and Mental Component Summary.
Nexrutine® is a patent-pending extract from the bark of the Phellodendron amurense tree, a traditional source of medicinals for more than 2000 years in Asia. “Nexrutine® has an excellent safety profile, not only from the long-term use of the plant material used to make this proprietary ingredient, but from extensive academic research on the active compounds and our own toxicology and human studies.” says Bob Garrison, pharmacist and CEO of Next.
The goal of the COX-2 class of anti-inflammatory compounds is to selectively inhibit the COX-2 enzyme without significantly inhibiting the stomach protective action of the COX-1 enzyme. Most selective COX-2 painkillers work by acting directly on the COX-2 enzyme once it has been formed. It has been speculated that some of the compounds that act directly on the COX-2 enzyme also act directly on other enzymes that are essential to maintaining a healthy heart. “Nexrutine® does not act directly on the COX-2 enzyme and has no significant action on the protective COX-1 enzyme.” says Garrison. “Nexrutine® kills pain and blocks inflammation in part by inhibiting the gene expression of the COX-2 enzyme without acting directly on the enzyme itself. We believe that Nexrutine’s® safety is in part due to the fact that it has a different mechanism of action than synthetic compounds in this class.”
Previously, a 50-subject consumer study with Nexrutine® demonstrated that 8 out of 10 subjects agreed that Nexrutine® is a safe, effective and rapidly acting dietary supplement that helps avoid or relieve the general aches and pains associated with physical activity or over-exertion. Two out of three subjects agreed that Nexrutine® achieved the following: eases soreness in joints and muscles, makes everyday activities more comfortable, relieves aching joints, and relieves muscle aches. The product was judged to be gentle on the stomach by 86 % of the subjects.
Nexrutine® is available to manufacturers of dietary supplements as a stand-alone product, or as an ingredient in combination formulas. Next Pharmaceuticals, Inc. is a research and development company that markets its patented or patent-pending ingredients to dietary supplement, food, and beverage companies focused on products for healthy living. For more information on Nexrutine® or Next’s other ingredients, visit www.nextpharmaceuticals.com.
Next Pharmaceuticals, Inc.
949.450.0203 ext. 15